InsiderTrades

Form 4 for IMVT Immunovant, Inc.

Accepted 2023-01-13 00:00:00 ET · period of report 2023-01-11 · accession 0001764013-23-000010 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2023-01-13 2023-01-11 IMVT Butchko Julia G. Chief Dev, Tech. Off S - Sale $16.79 -60.5K 331.4K -15% -$1.02M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-01-11 S D 19 $15.16 391,890 D — — (F1) On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,407 of these RSUs vested on January 1, 2023. On August 3, 2021, the holder was granted 285,306 RSUs, as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 142,653 of these RSUs vested on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligations due in connection with the vesting and settlement of these tranches of the RSUs and do not represent a discretionary sale by the holder.
2 Common Common Stock 2023-01-11 S D 60,471 $16.79 331,419 D — — (F1) On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,407 of these RSUs vested on January 1, 2023. On August 3, 2021, the holder was granted 285,306 RSUs, as previously reported on a Form 4 filed on August 4, 2021, of which the remaining 142,653 of these RSUs vested on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligations due in connection with the vesting and settlement of these tranches of the RSUs and do not represent a discretionary sale by the holder. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.